5.0 PATIENT SELECTION 
5.1 Eligibility: 
A. Patients must have histologically confirmed metastatic, and/or 
unresec table , locally advanced melanoma, renal cell carcinoma, breast 
cancer or colon cancer for which curative measures do not exist or are 
no longer effective. Patients must have expected survivals of 6 months 
or less. Patients must be off all therapy for at least 1 month prior 
to beginning treatment. 
B. Women of child-bearing potential must have a negative pregnancy test. 
C. Patients must have a negative HIV test. 
D. Patients must have intact cell mediated immunity as manifest by a 
positive response to any one of a broad panel of skin tests including 
TB, mumps, Candida, and SKSD (Merieux skin test). Skin tests will be 
read at 24 and 48 hours. 
E. Patients must be free of systemic infection. 
F. Patients must have the following laboratory values: 
1. WBC > 2000/mm 3 
2. Platelet count > 50,000 
3. Bilirubin < 2mg/dl 
4. Creatinine < 2mg/dl 
G. Patients must have biopsy proven metastatic melanoma, breast cancer, 
renal cell cancer, or colon cancer that is measurable by physical exam, 
or radiologic immaging. 
H. Patients must be at least 18 years old. 
5.2 Ineligibility: 
A. Patients who fail to meet the above criteria. 
B. Patients who are hepatitis B surface antigen positive or HIV antibody 
positive . 
C. Patients who require steroids in any form- topical or systemic. 
D. Patients with a history of having had another cancer with the exception 
of basal cell or squamous cell carcinoma of the skin. 
E. Patients who have had therapy within 28 days 
[506] 
Recombinant DNA Research, Volume 16 
